160 related articles for article (PubMed ID: 33459229)
21. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
22. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?
Martinez A; Perez DI
J Alzheimers Dis; 2008 Oct; 15(2):181-91. PubMed ID: 18953107
[TBL] [Abstract][Full Text] [Related]
23. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
[TBL] [Abstract][Full Text] [Related]
24. Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease.
Sharma N; Tramutola A; Lanzillotta C; Arena A; Blarzino C; Cassano T; Butterfield DA; Di Domenico F; Perluigi M; Barone E
Neurobiol Dis; 2019 May; 125():176-189. PubMed ID: 30738142
[TBL] [Abstract][Full Text] [Related]
25. Glycogen synthase kinase-3 signaling in Alzheimer's disease.
Lauretti E; Dincer O; Praticò D
Biochim Biophys Acta Mol Cell Res; 2020 May; 1867(5):118664. PubMed ID: 32006534
[TBL] [Abstract][Full Text] [Related]
26. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
Leroy K; Boutajangout A; Authelet M; Woodgett JR; Anderton BH; Brion JP
Acta Neuropathol; 2002 Feb; 103(2):91-9. PubMed ID: 11810173
[TBL] [Abstract][Full Text] [Related]
27. Isoorientin, a GSK-3β inhibitor, rescues synaptic dysfunction, spatial memory deficits and attenuates pathological progression in APP/PS1 model mice.
Tan X; Liang Z; Li Y; Zhi Y; Yi L; Bai S; Forest KH; Nichols RA; Dong Y; Li QX
Behav Brain Res; 2021 Feb; 398():112968. PubMed ID: 33069740
[TBL] [Abstract][Full Text] [Related]
28. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease.
Kozikowski AP; Gaisina IN; Petukhov PA; Sridhar J; King LT; Blond SY; Duka T; Rusnak M; Sidhu A
ChemMedChem; 2006 Feb; 1(2):256-66. PubMed ID: 16892358
[TBL] [Abstract][Full Text] [Related]
29. Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
Jiang X; Zhou J; Wang Y; Chen L; Duan Y; Huang J; Liu C; Chen Y; Liu W; Sun H; Feng F; Qu W
Eur J Med Chem; 2020 Dec; 207():112751. PubMed ID: 32950908
[TBL] [Abstract][Full Text] [Related]
30. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.
Maqbool M; Mobashir M; Hoda N
Eur J Med Chem; 2016 Jan; 107():63-81. PubMed ID: 26562543
[TBL] [Abstract][Full Text] [Related]
31. miR-219-5p inhibits tau phosphorylation by targeting TTBK1 and GSK-3β in Alzheimer's disease.
Li J; Chen W; Yi Y; Tong Q
J Cell Biochem; 2019 Jun; 120(6):9936-9946. PubMed ID: 30556160
[TBL] [Abstract][Full Text] [Related]
32. Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
Khan I; Tantray MA; Alam MS; Hamid H
Eur J Med Chem; 2017 Jan; 125():464-477. PubMed ID: 27689729
[TBL] [Abstract][Full Text] [Related]
33. GSK-3 is essential in the pathogenesis of Alzheimer's disease.
Takashima A
J Alzheimers Dis; 2006; 9(3 Suppl):309-17. PubMed ID: 16914869
[TBL] [Abstract][Full Text] [Related]
34. Unravelling the Role of Glycogen Synthase Kinase-3 in Alzheimer's Disease-Related Epileptic Seizures.
Lin R; Jones NC; Kwan P
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456185
[TBL] [Abstract][Full Text] [Related]
35. 17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.
Shi HR; Zhu LQ; Wang SH; Liu XA; Tian Q; Zhang Q; Wang Q; Wang JZ
J Neural Transm (Vienna); 2008 Jun; 115(6):879-88. PubMed ID: 18217188
[TBL] [Abstract][Full Text] [Related]
36. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
Medina M; Avila J
Curr Pharm Des; 2010; 16(25):2790-8. PubMed ID: 20698823
[TBL] [Abstract][Full Text] [Related]
37. Personalized Medicine and Resurrected Hopes for the Management of Alzheimer's Disease: A Modular Approach Based on GSK-3β Inhibitors.
Arafa RK; Elghazawy NH
Adv Exp Med Biol; 2017; 1007():199-224. PubMed ID: 28840559
[TBL] [Abstract][Full Text] [Related]
38. Curcumin Decreases Hyperphosphorylation of Tau by Down-Regulating Caveolin-1/GSK-3β in N2a/APP695swe Cells and APP/PS1 Double Transgenic Alzheimer's Disease Mice.
Sun J; Zhang X; Wang C; Teng Z; Li Y
Am J Chin Med; 2017; 45(8):1667-1682. PubMed ID: 29132216
[TBL] [Abstract][Full Text] [Related]
39. Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons.
Takashima A; Honda T; Yasutake K; Michel G; Murayama O; Murayama M; Ishiguro K; Yamaguchi H
Neurosci Res; 1998 Aug; 31(4):317-23. PubMed ID: 9809590
[TBL] [Abstract][Full Text] [Related]
40. Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.
Hurtado DE; Molina-Porcel L; Carroll JC; Macdonald C; Aboagye AK; Trojanowski JQ; Lee VM
J Neurosci; 2012 May; 32(21):7392-402. PubMed ID: 22623685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
